SRPT vs VOR

Sarepta's 10x growth potential remains tightly linked to the successful, rapid commercialization of Elevidys, its gene therapy for Duchenne Muscular Dystrophy (DMD). While the expanded traditional approval in late 2023 significantly de-risked the regulatory path, market sentiment, as reflected in the market cap, has stabilized slightly from $1.94B to $1.97B since our last analysis 17 days ago, hal...

Vor Biopharma presents a compelling high-risk, high-reward opportunity, demonstrating 10x growth potential within 3-5 years if key clinical milestones are met. The company's 'Mine-Resistant™' platform for AML is highly innovative, aiming to enable more potent targeted therapies. A major positive development since the last analysis is the successful securing of a $110 million private placement in D...